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Abstract
Autoantibodies against the newly established autoantigen in type 1 diabetes, zinc transporter 8, ZnT8, are presented as two
types, ZnT8RAb and ZnT8WAb. The rs13266634 variant of the SLC30A8 gene has recently been found to determine the
type of ZnT8Ab. The aim of this study was to explore the impact of this genetic variant and the ZnT8Ab on the residual beta-
cell function during disease progression the first year after disease diagnosis in children with newly diagnosed type 1 diabetes.
This cohort consists of 257 children aged , 16 years, all patients were newly diagnosed with type 1 diabetes. A Boost-test was
carried out at 1, 6, and 12 months to characterize the residual beta-cell function. Carriers of the CC and CT genotype groups
of the rs13266634 SNP of the SLC30A8 gene had higher stimulated C-peptide levels the first year after onset compared with
those of the TT genotype group (29%, p ¼ 0.034). CC genotype carriers were highly associated with the presence of
ZnT8RAb subtype during disease progression (compared with TT, p , 0.0001). On the other hand, the TT genotype was
associated with the presence of ZnT8WAb subtype during disease progression (compared with CC, p , 0.0001).
The C allele of the SLC30A8 gene is associated with preserved beta-cell function in type 1 diabetes patients. The genetic
determination of the rs13266634 variant on the ZnT8Ab specificity is sustained the first 12 months after the diagnosis of type
1 diabetes in a pediatric cohort.
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Introduction
The T-cell-mediated beta-cell destruction in type 1
diabetes is directed against beta-cell antigens with
insulin, GAD-65, and islet cell antigen 512 being the
classical and well-known ones. These antigens
together identify 80% of the patients at clinical
diagnosis or at risk of developing type 1 diabetes [1].
Recently, the zinc transporter 8, ZnT8, has been
established as a new major autoantigen in type 1
diabetes [1]. Several studies [2,3] report a strong
genetic association between a nonsynonymous single-
nucleotide polymorphism, rs13266634, of the ZnT8
encoding gene, SLC30A8, and the type of ZnT8Ab
(either arginine (Arg/R)- or tryptophan (Trp/W)-
recognizing antibodies). This genetic determination of
an autoimmune reaction has not been described for
any of the other diabetes-related autoantibodies, and it
is not known if it is associated with the differences in
disease progression/severity or whether this specificity
is stable over time.
Variants of different non-HLA-diabetes risk genes
have been shown to influence beta-cell function up to
12 months after diagnosis. Previously, we reported the
effect of the insulin VNTR region on the residual beta-
cell function and the level of insulin autoantibodies
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(IAA) during disease progression in type 1 diabetes
children [4]. Furthermore, two classical type 2 diabetes
genes, the Kir6.2 and the PPARgamma, were found to
influence glycemic control during disease progression
in type 1 diabetes patients [5,6]. No association of the
ZnT8Ab’s or the rs13266634 variant with the reduced
beta-cell function in type 1 diabetes has been reported.
The rs13266634 variant has, however, been reported
to be associated with the development of T2D [7], and
has been associated with the reduced first-phase insulin
release following an intravenous glucose load in a
glucose-tolerant population [8].
The objective of this study was to investigate (1) the
association of the rs13266634 variant of the SLC30A8
gene and the ZnT8Ab’s with the residual beta-cell
function, (2) the stability of the epitope-specific
ZnT8Abs during disease progression, and (3) whether
HLA risk groups were significantly associated with the
ZnT8Ab titer levels in a cohort of children with new
onset type 1 diabetes.
Subjects and methods
Study populations from The Hvidoere Study Group on
Childhood
The study population was collected through The
Hvidoere Study Group on Childhood Diabetes and
is described in Mortensen et al. [9]. The cohort
included 126 girls and 131 boys, 84% of the patients
were white Caucasian, and age at clinical diagnosis
was 9.1 ^ 3.7 years (mean ^ SEM), body mass index
16.5 ^ 3.2 kg/m2, and HbA1c 11.2 ^ 2.1% at the time
of diagnosis. DKA (HCO3 # 15 mmol/l and/or
pH # 7.30) was present in 20.7% of the cases at the
time of diagnosis.
Exclusion criteria were suspected non-type 1
diabetes (type 2 diabetes, maturity-onset diabetes of
the young or secondary diabetes), decline of enroll-
ment into the study by patients or parents, and
patients initially treated outside of the centers for more
than 5 days. There were no significant differences with
respect to gender distribution, age, anthropometric
data, HbA1c at diagnosis, ethnicity, or family history of
diabetes between patients included and patients not
included into the study (data not shown). The
diagnosis of type 1 diabetes was according to the
World Health Organization criteria. The study was
performed according to the criteria of the Helsinki II
Declaration and was approved by the local ethic
committee in each center. All patients, their parents,
or guardians gave informed consent.
Stimulated C-peptide test
Residual beta-cell function (C-peptide) in response to
a Boost-test (6 ml/kg (max: 360 ml) of Boost/Sustacal
(Mead Johnson, Evansville, IN, USA; 237 ml ¼ 8 fl oz
contains 33 g carbohydrate, 15 g protein and 6 g fat, a
total of 240 kcal) was followed 1, 6, and 12 months
((^1 week) after diagnosis in all 257 children with
newly diagnosed type 1 diabetes. Blood was drawn
90 min after ingestion of the Booste drink. Serum
samples were labeled and frozen at 2208C until
shipment on dry ice. C-peptide was analyzed centrally.
Samples were thawed only once for RIA determi-
nation. Plasma C-peptide was analyzed by a fluor-
oimmunometric assay (AutoDELFIAe C-peptide.
Analytical sensitivity: better than 4.97 pmol/l coeffi-
cient of variation (CV) 5%).
Typing of the SLC30A8 gene
Genotyping of the rs13266634 variant of the ZnT8
gene, SLC30A8, was done both at KBioscience using
an in-house KASPar assay system and at Steno
Diabetes Center, Denmark, using a predesigned
TaqMan assay (Applied Biosystems, Foster City, CA,
USA) on a TaqMan 7900HT (Applied Biosystems).
The concordance rate between the two assayswas 97%.
HLA
Typing of the HLA-class II DRB1 locus was
performed by direct sequencing of exon 2 of DRB1
according to Immuno Histocompatibility Working
Group. The HLA risk groups were defined as follows:
high risk (DRB1 03/04, 04/04), moderate risk (DRB1
03/03, 04/08), and low risk (all other DRB1 genotype
combinations).
Diabetes-related autoantibodies (IAA, islet cell antibodies,
glutamic acid decarboxylase, IA-2A, and ZnT8Ab)
IAA. Insulin antibodies were measured by a
modification of the method described by Williams
et al. [10]. The cut-off limit for positivity is 1.56
relative units (RU), representing the 99th percentile in
a group of 371 non-diabetic subjects.
Islet cell antibodies. Islet cell antibodies (ICA) of the IgG
class were detected by indirect immunofluorescence
using commercial Primate Pancreas slides from
INOVA. The sera were screened at a dilution of
1:2 and FITC-labeled anti-human IgG (Dako,
Copenhagen, Denmark) was used as conjugate.
Glutamic acid decarboxylase. Antibodies to the 65 kDa
isoform of glutamic acid decarboxylase (GADA) were
quantified by a direct radioimmunoassay (Diamyd
Anti-GAD-65 RIA; Diamyd Diagnostics, Stockholm,
Sweden) according to the protocol provided by the
manufacturer. Sera were run in duplicate, and the
results were read on a gamma counter (Wizard 1470;
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Wallac/PerkinElmer, Turku, Finland) and calculated
from a standard curve. The cut-off limit was
9.5 units/ml and the intra- and interassay coefficients
of variation were 2.4 and 3.6%, respectively.
IA-2A. Antibodies to the protein tyrosine
phosphatase-related IA-2 molecule (IA-2A) were
analyzed with a radiobinding assay as previously
described [11]. The results were expressed as RU
based on a standard curve run on each plate using an
automated calculation program (MultiCalc; Wallac).
The limit for IA-2A positivity (0.77 RU) was set at the
99th percentile in 374 non-diabetic children and
adolescents. The interassay CV was,12%. This assay
had a disease sensitivity of 72% and a specificity of
100% based on the 2005 Diabetes Autoantibody
Standardisation Programme workshop.
ZnT8Ab
Subcloning of the C-Terminal construct (Arg 325) ZnT8R
from pCDNA3.1 to generate pThZnT8R
The original C-terminal cDNA construct coding for
Arg at position 325 [1] was a kind gift from John C
Hutton (Barbara Davis Center for Childhood Dia-
betes, University of Colorado at Denver and Health
Sciences Center, Aurora, CO, USA). The insert was
subcloned into the pTnTe vector (Promega, Madi-
son, WI, USA) as described [12,13]. The ZnT8W
variant was generated by site-directed mutagenesis
and confirmed by DNA sequencing [12,13].
Coupled in vitro transcription/translation of cDNA for
ZnT8R and ZnT8W
The coupled in vitro transcription/translation of the
ZnT8R in the pCDNA3.1 vector and the two new
plasmids, pThZnT8R and pThZnT8W, were per-
formed as follows. The reaction mixture of 2mg
ZnT8R in the pCDNA3.1 vector, pThZnT8R or
pThZnT8W, 50ml TNTw rabbit reticulocyte lysate,
4ml TNTw reaction buffer, 2ml amino acid mixture
minus methionine, 2ml RNasinw Ribonuclease
inhibitor (Promega), 2ml SP6 RNA Polymerase, 4ml
35S-methionine (Amersham Int., Amersham, Bucking-
hamshire, UK, .1000 Ci/mmol), and nuclease-free
water to a final volume of 100mlwas incubated for 90 min
at 308C with shaking (300 rpm in Eppendorf Thermo-
mixer comfort, Eppendorf, www.eppendorf.com).
The translation product was immediately subjected
to gel filtration on Illustrae NAP-5 Columns (GE
Healthcare Bio-Sciences AB, Uppsala, Sweden) and
percent radioactivity incorporated into protein was
counted (1450 MicroBeta TriLux Microplate
Scintillation-Luminescence Counter, Perkin Elmer
Life and Analytical Sciences, Shelton, CT, USA,
www.perkinelmer.com). The percent radioactivity
for ZnT8R in the pCDNA3.1 vector was 10 ^ 3%
(mean þ SD) compared to .40% for each new
plasmids including pThZnT8R and pThZnT8W.
The translation product corresponding to the most
C-terminal part of ZnT8 protein (aa268-aa369) for
ZnT8R and ZnT8W was demonstrated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and autoradiography.
Autoantibody radiobinding assay for ZnT8R and ZnT8W
The RBA for the individual variants was performed
separately with 5ml of sera essentially as described
[12]. Duplicate serum samples were incubated over
night at 48C with 60ml labeled antigen diluted in
antigen buffer (150 mM NaCl, 20 mM Tris, pH 7.4,
0.15% Tween20, 0.1% BSA) at a final concentration
425 ^ 25 cpm/ml using MicroWelle plates (Nunc,
www.nalgenunc.com). Antibody bound was separated
from free-labeled antigen with Protein A Sepharose
(20%) and the radioactivity determined in a beta-
counter (a 1450 MicroBeta TriLux Microplate
Scintillation-Luminescence Counter, (Perkin Elmer
Life and Analytical Sciences, www.perkinelmer.com).
The results were expressed in in-house units using two
different standard curves of type 1 diabetes-sera
positive for each of ZnT8R and ZnT8W, respectively.
Positivity for ZnT8RAb was defined as titer values
$60 U/ml and for ZnT8WAb $58 U/ml. Out of 257
patients, 251 completed ZnT8Ab measurements.
Statistics
The association between the rs13266634 variant and
the ZnT8Ab level was determined by logistic
regression with age, sex, HLA risk groups, and DKA
at onset as confounding factors at all three visits (1, 6,
and 12 months after onset). Stimulated C-peptide
(logarithmic) and insulin dose-adjusted HbA1c
(IDAA1c) [14] were analyzed as dependent variables
in two separate multiple regression models by a
compound symmetrical repeated measurement
model of all time points with rs13266634 genotype,
ZnT8W/RAb levels, sex, age, positivity for other
diabetes-related autoantibodies (IAA, GADA, islet
cell autoantibodies (ICA), insulinoma-associated anti-
gen-2 (IA-2A)), and HLA risk groups (high (DRB1
03/04, 04/04), moderate (DRB1 03/03, 04/08), low (all
other genotype combinations)) as covariates. P-values
below 0.05 were considered statistical significant.
Results
Frequency of ZnT8Ab
One month after diabetes onset, 68% of the patients
tested positive for either one or both of the ZnT8Ab
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variants (ZnT8RAb and/or ZnT8WAb). At 6 and
12 months after onset, the overall positivity was
nonsignificantly decreased to 63 and 61%, respect-
ively. The frequency of patients tested positive for
ZnT8RAb was highest throughout the study period
compared with the frequency of patients tested
positive for ZnT8WAb ( p , 0.0001) (Figure 1).
In the same Hvidoere cohort, we previously
diagnosed 24 out of 261 (9.2%) pancreatic antibody
negative (ICA, GADA, IA-2A) children with new
onset type diabetes. When we include the measure-
ment of ZnT8Ab, six patients from this autoantibody
negative subgroup were identified as ZnT8Ab positive
(five patients ZnT8RAb positive and one patient
positive for both ZnT8Ab variants), reducing the
frequency of Ab-negative patients by 25% (Table I) in
the whole cohort.
ZnT8Ab titer level associates with age-at-onset
The frequency of ZnT8RAb positive was significantly
higher ( p ¼ 0.03, 0.03, and 0.02 at 1, 6, and 12
months after onset, respectively) in patients above
5 years (n ¼ 133) at onset compared with the patients
below 5 years (n ¼ 20) at onset (Table II). By contrast,
the prevalence of the ZnT8WAb was independent of
age-at-onset (data not shown).
SLC30A8 rs13266634 genotype in relation to
residual beta-cell function
In a co-dominant model (comparing differences in
stimulated C-peptide between all three genotype
groups), carriers of the SLC30A8 rs13266634 TT
genotype had significantly lower stimulated C-peptide
1 month after onset compared with CC genotype carriers
(est.: 0.644 pmol/l, p ¼ 0.049). The CT and CC
genotype carriers showed similar levels of stimulated
C-peptide which allowed us to use a dominant model
with respect to the C allele (CT þ CC versus TT) in a
mixed model including all visits 1, 6, and 12 months
after onset. The TT genotype carriers showed 29%
lower stimulated C-peptide levels compared with the
CT þ CC genotype carriers during the study period
(est.: 0.71 pmol/l, p ¼ 0.034) (Figure 2). Adding a
gene*visit interaction term to model showed no
differential gene effect over time ( p ¼ 0.53).
IAA, GADA, ICA, IA-2A, and ZnT8Ab in
relation to glycemic control and residual
beta-cell function
The observed progressive decline in ZnT8Ab during
disease progression was concurrent with the decline in
stimulated C-peptide (Figure 3). There was, however,
no association between positivity or titer levels of
ZnT8Ab and the residual beta-cell function as
estimated by stimulated C-peptide at any time points
during disease progression ( p ¼ 0.21 (Trp) and
p ¼ 0.95 (Arg)). Nor can the ZnT8Ab measured
Table I. The distribution of Ab-positive and negative patients in
the Hvidoere cohort according to GAD, IA-2A, ICA, and ZnT8Ab
measured 1 month after disease onset (n ¼ 249).
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Figure 1. Positivity of ZnT8Ab (either ZnT8RAb and/or
ZnT8WAb) in children with type 1 diabetes 1, 6, and 12 months
after disease onset. * indicate significant difference in ZnT8Ab
positivity between the two subtypes.
Table II. Frequency of patients positive for ZnT8RAb according to
age-at-onset.
Time after
1 month 6 months 12 months
Age-at-onset
,5 years .
47%
64%
ðp ¼ 0:03Þ
40%
59%
ðp ¼ 0:03Þ
37%
57%
ðp ¼ 0:02Þ
x 2-test for differences in ZnT8RAb positivity between age groups:
,5 years (n ¼ 20) and .5 years (n ¼ 133) ( p-values).
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Figure 2. The stimulated C-peptide levels during disease
progression according to a dominant gene model, the TT
genotype carriers of the rs1326634 variant versus the CT þ CC
genotype carriers.
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1 month after type 1 diabetes diagnosis predict the
stimulated C-peptide level 12 months after disease
onset ( p ¼ 0.30 (Trp) and p ¼ 0.19 (Arg)).
The same lack of predictive value was also evident for
the ICA and IA-2A antibodies (data not shown). On
the contrary, the IAA and GADA antibodies at 1 month
can predict stimulated C-peptide 12 months after
clinical diagnosis (est.: 32% lower C-peptide, p ¼ 0.02,
est.: 39% lower C-peptide, p ¼ 0.0004). GADA at 1
month also predicts Hba1c at 12 months (est.: 0.48%,
p ¼ 0.012), whereas none of the other diabetes-related
autoantibodies predicts HbA1c at 12 months.
ZnT8Ab titer levels according to HLA risk genes
The ZnT8RAb levels were significantly higher in
carriers of the low HLA risk groups compared with
carriers of the moderate and high HLA risk groups 1
and 6 months after onset ( p ¼ 0.04) and borderline
significant at 12 months after onset ( p ¼ 0.06). The
levels of the ZnT8RAb were comparable in the
moderate and high risk groups (Figure 4), justifying a
model in which carriers of the low HLA risk group are
compared with the moderate and high HLA risk
groups. There were no significant differences in the
distribution of ZnT8WAb according to HLA risk
groups (data not shown).
Association between the rs13266634 gene variant
and ZnT8Ab specificity
The genotype distribution in this cohort (CC 46.8%,
CT 41.7%, and TT 11.5%) was in Hardy–Weinberg
equilibrium. We find the rs13266634 SNP is highly
associated with the ZnT8Ab type 1 month after
disease onset and this association is sustained during
disease progression (6 and 12 months after disease
onset). The CC genotype carriers have significantly
higher ZnT8RAb compared with the TT genotype
carriers (1 month p , 0.0001, est.: 370 U/ml)
(Figure 5A).
The heterozygous carriers have intermediate values
for both ZnT8Ab variants. The opposite picture was
evident for the ZnT8WAb, in which the TT carriers
have a significantly higher ZnT8WAb compared with
the CC genotype carriers (1 month p , 0.0001, est.:
374 U/ml) (Figure 5B). In patients only responding to
either ZnT8RAb or ZnT8WAb, the relationship with
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Figure 3. The concordant decline in stimulated C-peptide and the
two ZnT8Ab subtypes, ZnT8RAb and ZnT8WAb, during disease
progression.
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Figure 4. The distribution of ZnT8RAb during disease
progression according to DRB1 HLA risk genes. The mean
ZnT8RAb values ^ SEM are plotted against the three HLA risk
genotype groups, low, moderate, and high. * indicate significance
differences in ZnT8RAb level between genotype groups.
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Figure 5. Association between the rs13266634 variant and the
ZnT8Ab presentation during disease progression. (A) The
ZnT8RAb distribution according to CC, CT, and TT genotype
groups. (B) The ZnT8WAb distribution according to these
genotype groups.
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the rs13266634 variant was indeed stronger. A 4.6-
fold higher ZnT8RAb frequency was seen among CC
carriers compared with the CT carriers, whereas the
frequency of ZnT8WAb was 15.5-fold higher among
the TT carriers compared with CT carriers (Table III).
Discussion
This study suggests an association between the
rs1326634 variant of the SLC30A8 gene and the
residual beta-cell function in children with new onset
type 1 diabetes and a relation between the HLA risk
groups and the titer of ZnT8RAb. Furthermore, a
strong relation between the rs13266634 variant of the
SLC30A8 gene and the specificity of the ZnT8Ab was
found. This is a newly described phenomenon
involved for type 1 diabetes associated autoantibodies
[2]. Our study supports this association and further-
more extends these observations into a pediatric
population from the time of disease onset and the
following year.
In the present pediatric cohort, there is a
nonsignificant decreasing trend of positivity for
ZnT8Ab from onset to 12 months after diagnosis for
both Arg- and Trp-recognizing autoantibodies
(Figure 1). This is similar to the observed pattern
of GADA, IA-2A, and ICA in the same cohort [9],
whereas IAA tends to increase from onset due to
insulin treatment. A relation between age-at-onset and
positivity for ZnT8RAb was previously indicated in a
mixed cohort of children and adults, in which the
prevalence of ZnT8Ab was low in the very young
children but increased dramatically from 3 years
onward, peaked at 80% in late adolescence, and
tended to decline thereafter [2].
Our study supports this observation because the
youngest patients (0–5 years) presented with the
lowest ZnT8RAb levels, the age and ZnT8RAb
correlation sustained during disease progression
(Table II). This difference suggests that the peak of
autoimmune response occurred before the time of
onset for this age group. Interestingly, this effect of age
was not seen for ZnT8WAb levels.
When we analyzed ZnT8Ab in this cohort, an
additional 2.3% of the GADA, ICA, and IA-2A
negative patients were ZnT8Ab positive (Table I).
Lampasona and coworkers have previously identified
an additional 1.4% of autoantibody negative subjects
as autoantibody positive when testing for ZnT8Ab
in an adult-onset type 1 diabetes cohort [15]. In
agreement with the previously reported 26%
ZnT8Ab-positivity rate among patients classified as
autoantibody negative [1], we find that 25% of the
children classified as autoantibody negative in our
study were ZnT8Ab positive, either for the Arg or
Trp variant. Therefore, in clinical practice, the
inclusion of ZnT8Ab may help to differentiate clinical
phenotypes.
Our study suggests a functional impact of the
rs13266634 variant of the SLC30A8 gene on
progression of the disease. Analyzing the gene effect
in a multiple regression analysis including all three
visits (1, 6, and 12 months) in the same model we
found, that carriers of the TT genotype had
significantly lower residual beta-cell function 12
months after disease diagnosis. This effect was,
however, primarily due to the difference observed at
1 month (Figure 2).
The rs13266634 has previously been shown to
associate with T2D [7] and reduced first-phase insulin
release in a glucose-tolerant population, although this
effect appeared to be associated with the CC genotype
[8]. At first this may seem contradictory, but assuming
a reduced insulin secretory capacity in C-allele
carriers, this may turn out to be a beta-cell protective
effect in type 1 diabetes. Insulin is a major autoantigen
in type 1 diabetes, so it seems plausible to hypothesize
that reduced insulin secretory capacity associated with
the C-allele and in the presence of insulin directed
autoimmunity will reduce insulin antigen presen-
tation, reduce beta-cell stress, and slow down
autoimmune beta-cell destruction.
On the contrary, the T-allele associated with higher
insulin secretory capacity should in the presence of
insulin-directed autoimmunity lead to higher insulin
antigen presentation, beta-cell stress, and auto-
immune beta-cell destruction. In accordance with
this hypothesis, we find that TT-genotypes have lower
residual beta-cell function than CC-genotypes.
Table III. Prevalence of ZnT8Ab according to rs13266634 genotype. ZnT8Ab (Trp and/or Arg) was measured in serum from new onset type
1 diabetes patients 1 month after onset.
rs13266634 genotype
XX (243)
CC (114) CT (101) TT (28)
Response n % n % n % n % P
Arg probe 149 61.8 88 77.2 54 53.5 7 25.0 ,0.0001
Trp probe 97 39.9 31 27.2 46 45.5 20 71.4 ,0.0001
Arg only 68 28.0 57 50.0 11 10.9 0 0.0 ,0.0001
Trp only 16 6.9 0 0.0 3 3.0 13 46.4 ,0.0001
P-values were calculated by Fisher’s exact test comparing ZnT8Ab positivity to rs13266634 genotype frequencies.
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A concurrent decline in stimulated C-peptide and
ZnT8Ab titers (Figure 3) was also previously found in
a smaller type 1 diabetes population (n ¼ 21), neither
of the two studies found a correlation between
ZnT8Ab and residual beta-cell function during the
study period [16]. In our study, ZnT8Abs at 1 month
did not predict residual beta-cell function at 12
months, although we did find that the level of IAA and
GADA at 1 month after diagnosis was associated with
a more rapid loss of residual beta-cell function.
Together, these observations suggest that the
ZnT8Abs alone do not play a major role in the
autoimmune destruction of the beta cells, whereas
IAA and GADA seem to do so.
The finding that carriers of the HLA low risk alleles
have significantly higher ZnT8RAb 1 and 6 months
after clinical onset (Figure 4) is most likely a spurious
finding as similar was not observed for the other
more pathogenically related autoantibodies, GADA
and, IAA.
The strong association between the rs13266634
variant and the two types of the ZnT8Ab throughout
initial clinical disease progression suggests that
epitope switching did not occur during the study
period (Figure 5). That Trp-recognizing ZnT8Ab was
found in a few CC genotype carriers (encoding Arg)
indicate, however, that the specificity is not 100% but
the association between the genotype and ZnT8Ab
subtype is complete when analyzing patients only
presenting ZnT8RAb, or only presenting ZnT8WAb
(Table III).
Our study confirms the genotypic specificity of
ZnT8Ab in a cohort of new onset type 1 diabetes
children, and although we did not observe association or
predictive value of these autoantibodies on the disease
progression, the role of ZnT8 as an autoantigen in the
pathogenesis of type 1 diabetes should be further
explored, like insulin and GAD65 have been, in immune
intervention trials with recombinant ZnT8 epitopes.
The role of the rs13266634 variant on beta-cell function
during disease progression in type 1 diabetes patients
needs confirmation from the studies of disease
progression in other type 1 diabetes populations.
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